MapLight Therapeutics, Inc. (MPLT) research
MapLight Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.77
- As of
MapLight Therapeutics, Inc. (MPLT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
As of . Source: SEC EDGAR filings for MPLT. Method and limitations.
Share the MPLT intelligence card
See MPLT live in the terminal
Track MPLT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live MPLT terminal, freeActive signals for MPLT
- highCONSENSUS_BUY
3 tracked funds increased MPLT this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased MPLT this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +824% to MPLT (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in MPLT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +12130% to MPLT (2026Q2)
FREE, NO ACCOUNT
Every signal on MPLT, as it fires
You are seeing 5 of 22 signals recorded on MPLT since 2026-05-17.
The five above landed across 2 days. The other 17 were recorded on 3 other days. 15 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MPLT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 56565P103 · 2026Q2 | $4.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 56565P103 · 2026Q2 | $923K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 56565P103 · 2026Q2 | $322K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 56565P103 · 2026Q2 | $249K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MPLT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MPLT against its peers
MPLT's return on equity of -35.2% ranks in the 67th percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | MPLT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 14.2M | n/a | 15 |
| Operating margin | n/a | -315.4% | n/a | 12 |
| Net margin | n/a | -294.7% | n/a | 12 |
| Return on equity | -35.2% | -67.9% | 67 | 22 |
Peers (22): ASMB, CTNM, KYTX, AUTL, PBYI, ENTX, OVID, CAPR, TECX, RGNX, ARVN, INDP, OCS, PRME, EPRX, SPRY, PRTA, RLMD, ALLO, CABA, IRD, EDIT. Left out: VOGX (no annual filing), EIKN (no annual filing), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MPLT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MPLT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MPLTand get the insider, 13F, options, and confluence read in one view.